Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD?

CON

Jay Wish, MD
DISCLOSURES

• Consultant – Fibrogen
• Advisory Boards – AstraZeneca, Akebia/Otsuka, GSK, Vifor Pharma, Rockwell Medical, Amgen, CSL Behring
• Speakers Bureaus – AstraZeneca, Akebia
THE PROMISE OF HIF-PHI vs ESAs (CIRCA 2019)

• Lower plasma EPO levels than with ESAs would decrease ESA off-target effects leading to improved MACE outcomes
• Decreased ESA off-target effects (MACE) would allow for higher Hgb targets and improved quality of life
• Improved iron mobilization would lead to decreased IV iron requirements in NDD and DD patients
• Improved iron mobilization would lead to ability to achieve target Hb level in ESA-hyporesponsive patients
Hypoxia-Inducible Factors (HIFs) Maintain Oxygen Homeostasis

> 4,000 known target genes

- **EPO**
  - Erythropoiesis
  - Increase O₂ delivery

- **VEGF**
  - Angiogenesis

- **IGF2**
  - Inhibition of apoptosis

- **GLUT**
  - Glycolytic enzymes
  - Metabolic adaptation

- **Survive O₂ deprivation**

**O₂ Demand** ➔ **Hypoxia** ➔ **O₂ Supply**

HIF-1α

HIF-2α

HIF-1β

HIF-1β

Semenza, NKF HIF-Phi Workshop, 2019
PHD inhibitors not only activate HIF but may also activate structurally-related 2-OG dependent enzymes.
CONSEQUENCES OF HIF ACTIVATION IN CANCER CELLS

- Cell immortalization
- Maintenance of cancer stem cells
- Genetic instability
- Autocrine growth factor signaling
- Vascularization
- Glucose/Energy metabolism
- Invasion and metastasis
- Immune evasion
- Chemotherapy and radiation resistance

Semenza, NKF HIF-PHI Workshop, 2019
CV EVENTS IN HIF-PHI PHASE 3 CLINICAL TRIALS VS ESA

• Roxadustat
  • Increased MACE vs darbeo in DD patients in ITT analysis (HR 1.14 [1.00, 1.30])
  • Increased all cause mortality in DD patients in ITT analysis (HR 1.17 [1.02, 1.35])
  • Increased MACE vs ESA in PYRENEES study of DD patients: ITT (HR 1.54 [1.09, 2.16]), OT+7 HR 1.54 (1.04, 2.28)
  • RR for 3.9 serious DVT and 1.5 for serious vasc access thrombosis in DD patients
**On-Study Analysis (Sensitivity)**

- **MACE ITT DD**
  - Roxadustat
  - Epoetin alfa

  HR (95% CI) = 1.14 (1.00, 1.30)

- **ACM ITT DD**

  HR (95% CI) = 1.17 (1.02, 1.35)

**On-Study Analysis**

- **ACM ITT DD PYRENEES**
  - EPO/Darbepoetin alfa
  - Roxadustat

  HR (95% CI) = 1.54 (1.09, 2.16)

- **ACM OT+7 PYRENEES**

  HR (95% CI) = 1.54 (1.04, 2.28)

Roxadustat FDA Briefing Document, 2021
Time to First Thromboembolic Event, NDD and DD Pooled Studies; All Adverse Events (Serious and Non-serious)

NDD Population

DD population

Roxadustat

Placebo

Roxadustat

Epoetin alfa

% with Event

Time to First Event (Months)
VADADUSTAT AND MACE IN GLOBAL PHASE 3 STUDIES: NDD

No. at Risk
Vadadustat 1739 1668 1587 1301 1108 931 759 588 459 311 185 97 30 4 1 0
Darbepoetin alfa 1732 1674 1618 1329 1129 961 774 621 505 346 213 103 43 6 0

Hazard ratio, 1.17 (95% CI, 1.01–1.36)

Vadadustat (382 events)
Darbepoetin alfa (344 events)

Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients

Huanhuan Chen MS\(^1,2\) | Qingfeng Cheng MD\(^3\) | Jiuxiang Wang MS\(^1\) | Xiaofang Zhao MS\(^1\) | Shenyin Zhu PhD\(^1\)

<table>
<thead>
<tr>
<th>Adverse events</th>
<th>RR (95% CI)</th>
<th>P value</th>
<th>(I^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>1.15 (0.91,1.43)</td>
<td>0.25</td>
<td>35.80%</td>
</tr>
<tr>
<td>Nausea</td>
<td>1.34 (0.95,1.89)</td>
<td>0.09</td>
<td>51.00%</td>
</tr>
<tr>
<td>Vomiting</td>
<td>1.30 (1.02,1.65)</td>
<td>0.03</td>
<td>12.20%</td>
</tr>
<tr>
<td>Headache</td>
<td>1.27 (1.05,1.53)</td>
<td>0.01</td>
<td>0.00%</td>
</tr>
<tr>
<td>Hyperkalemia</td>
<td>1.14 (0.69,1.89)</td>
<td>0.61</td>
<td>53.30%</td>
</tr>
<tr>
<td>Hypertension</td>
<td>1.02 (0.89,1.17)</td>
<td>0.76</td>
<td>0.00%</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>0.94 (0.71,1.25)</td>
<td>0.69</td>
<td>55.70%</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>1.16 (0.88,1.52)</td>
<td>0.29</td>
<td>20.90%</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>0.72 (0.51,1.02)</td>
<td>0.06</td>
<td>0.00%</td>
</tr>
<tr>
<td>Thrombosis events</td>
<td>1.31 (1.05,1.63)</td>
<td>0.02</td>
<td>44.50%</td>
</tr>
<tr>
<td>MACE</td>
<td>1.02 (0.90,1.14)</td>
<td>0.80</td>
<td>0.00%</td>
</tr>
<tr>
<td>Heart failure</td>
<td>0.95 (0.72,1.26)</td>
<td>0.73</td>
<td>7.00%</td>
</tr>
</tbody>
</table>

*Favors HIF-PHI* | *Favors ESA*
WHAT ABOUT CANCER?

- In TREAT study, among 188 patients in group assigned to darbepo with pre-existing cancer there were 14 cancer deaths, as opposed to 1 cancer death among 160 patients with pre-existing cancer assigned to placebo (p<0.002).
- FDA has black-box warning regarding tumor progression and decreased survival with ESAs.

WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE

- In NDD patients (ASCEND-ND), daprodustat increased cancer risk by almost 50% vs darbeapo.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Daprodustat (N=1937)</th>
<th>Darbepoetin Alfa (N=1933)</th>
<th>Relative Risk (95% CI)</th>
<th>P Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer-related death or tumor progression or recurrence</td>
<td>72 (3.7) 82</td>
<td>49 (2.5) 67</td>
<td>1.47 (1.03–2.10)</td>
<td>0.04</td>
</tr>
</tbody>
</table>

DOI: 10.1056/NEJMoA2113380
Table 2. Key policy recommendations from the institute for clinical and economic review regarding roxadustat^{57}

- Clinicians should follow the principle of shared decision making to ensure that the values of patients with diverse needs and perspectives on risks and benefits of different treatments are at the heart of all treatment decisions.
- Clinicians should have decision support tools and invest the time needed for shared decision making given the uncertainty and potential variability in patients’ values about an oral treatment option for anemia in chronic kidney disease (CKD).
- Given the level of uncertainty about the benefits vs. harms and the long-term effect of using roxadustat compared with ESAs, we strongly suggest a mandate for a registry or other rapid and comprehensive postmarketing assessment.
- The manufacturer and researchers should avoid focusing primarily on hemoglobin levels and the need for transfusion. Future research should expand outcomes measured to include patient-relevant outcomes, such as quality of life, functional status, fatigue, overall cardiovascular events, and mortality, in addition to the need for transfusion.
- Researchers should conduct real-world comparative studies of roxadustat vs. ESAs that evaluate a broad set of patient subgroups, including ethnic and racially diverse populations and those who are hyporesponsive to ESAs.
- Given the mechanism of action for roxadustat, patients were excluded from clinical trials if they had acute coronary syndrome, acute stroke, acute seizure, or thrombotic event within the last 12 weeks. Until further data are gathered, clinicians should consider delaying treatment with roxadustat for patients with this clinical scenario.
- Given that the evidence is not adequate to distinguish clinical benefit and that there are more data and years of clinical experience with ESAs, some payers may wish to consider stepping through ESAs if they are substantially lower priced than roxadustat before obtaining coverage for a more expensive option.

Table 3. Key recommendations of the Asian-Pacific Society of Nephrology regarding the use of hypoxia-inducible factor prolyl hydroxylase inhibitors^{54}

- Physicians can consider HIF-PHI inhibitors as an alternative to ESA in correcting and maintaining hemoglobin level in NDD- and DD-CKD patients.
- Iron deficiency should be corrected (ferum < 100 mg/dl and TSAT > 20%) before HIF stabilizers are initiated.
- HIF-PHI inhibitors may be preferred to ESAs:
  - If frequency of hospital/clinic visits or invasiveness of injections is a burden
  - If target hemoglobin cannot be achieved with ESA
- Administration of HIF-PHI inhibitors should be undertaken with great caution, if at all, in patients with known malignancy.
- Given the theoretical risk of retinopathy, prompt ophthalmologic evaluation should be ordered for patients who report visual disturbance after drug initiation.
- Regular monitoring of liver function should be considered given uncommon but possible risk of liver injury from HIF-PHI inhibitors.
- Serum potassium should be monitored during treatment with HIF-PHI inhibitors given reports of hyperkalemia in clinical trials.
- Although there are no data suggesting HIF-PHI inhibitors increase blood pressure, attention should be paid to blood pressure control in patients receiving these agents.
- Given theoretical effects on pulmonary hypertension, attention should be paid to changes in cardiac function in patients receiving HIF-PHI inhibitors.
- Limited use of HIF-PHI inhibitors is suggested in patients with a history of thrombotic events.
- Cyst size should be monitored in patients with polycystic kidney disease receiving HIF-PHI inhibitors.

KI Reports, 6:2540–2553, 2021
THE PROMISE OF HIF-PHIs VS ESAs (CIRCA 2019-2021)

- Lower plasma EPO levels than with ESAs would decrease ESA off-target effects leading to improved MACE outcomes. Not true, MACE may actually be worse.
- Decreased ESA off-target effects (MACE) would allow for higher Hgb targets and improved quality of life. Not true; no improvement in QOL vs. ESAs in head-to-head studies.
- Improved iron mobilization would lead to decreased IV iron requirements in NDD and DD patients. May be true, but how does that translate into improved outcomes?
- Improved iron mobilization would lead to ability to achieve target Hb level in ESA-hyporesponsive patients. May be true, but no studies done specifically targeting ESA-hyporesponsive patients.
**SUMMARY**

**ESAs: The devil we know**
- MACE
- ↑Hgb
- Thrombosis
- Cancer

**HIF-PHIs: The devil we don’t know**
- Upper GI Erosions
- Hyperkalemia
- Cyst Progression
- Fibrogenesis
- Cancer
- Thrombosis
- ↑Hgb
- MACE
- Infection
- Pulmonary Hypertension
- Retinopathy